Nakao, Shintaro http://orcid.org/0000-0003-4200-0052
Kusuhara, Sentaro http://orcid.org/0000-0002-6458-539X
Murakami, Tomoaki http://orcid.org/0000-0002-0314-8807
Funding for this research was provided by:
Novartis Japan (None, None, None)
Article History
Received: 14 December 2023
Revised: 10 May 2024
Accepted: 14 June 2024
First Online: 12 July 2024
Declarations
:
: This review article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Not applicable.
: Shintaro Nakao reports consulting fees from Chugai Pharmaceutical, Boehringer Ingelheim, Kowa, Novartis, and Riverfield; and travel reimbursements and speaker fees from Alcon, Bayer, Boehringer Ingelheim, Canon, Chugai Pharmaceutical, HOYA, JFC Sales Plan, Kowa, Machida, Mitsubishi Tanabe, MSD, Novartis, Novo Nordisk, Otsuka, Santen, Senju, and Wakamoto. Sentaro Kusuhara reports payment for lectures or supervision from AbbVie Japan, Bayer Yakuhin, Boehringer Ingelheim, Chugai, Eisai, Kowa, Mitsubishi Tanabe, Nippon Kayaku, Novartis Pharma K.K., Santen, and Senju; grants from AMO Japan and Bayer Yakuhin; receipt of drugs from Clinigen K.K.; and patent royalties from Charmant. Although Sentaro Kusuhara is an editorial board member of Graefeās Archive for Clinical and Experimental Ophthalmology, he had no involvement in the peer review process for this article. Tomoaki Murakami reports payment for lectures or supervision from Bayer Yakuhin, Chugai Pharmaceutical, HOYA, Kowa, Novartis Pharma K.K., Santen, and Senju; and consulting fees from Boehringer Ingelheim.